Prescription drug · BLA
Selarsdi (ustekinumab-aekn) NDC 51759-505
Ustekinumab-aekn 45 mg/.5mL · Injection, Solution · Subcutaneous · Teva Pharmaceuticals USA, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 51759-505-13 | 51759050513 | 1 VIAL in 1 CARTON (51759-505-13) / .5 mL in 1 VIALMarketed from Oct 16, 2025 | |
| 51759-505-32 | 51759050532 | 1 TRAY in 1 CARTON (51759-505-32) / 1 SYRINGE, GLASS in 1 TRAY / .5 mL in 1 SYRINGE, GLASSMarketed from Mar 12, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Selarsdi
- Generic name (nonproprietary)
- ustekinumab-aekn
- Active ingredients
- Ustekinumab-aekn — 45 mg/.5mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761343
- Marketing start
- Listing expires
- Other FDA classes
- Interleukin-12 Antagonists (Mechanism)Interleukin-23 Antagonists (Mechanism)
- Identifiers
- Product ID 51759-505_6faa1c86-d0f8-4260-aeca-8232ab8be678SPL ID 6faa1c86-d0f8-4260-aeca-8232ab8be678SPL set ID 87f75b59-e48b-47c7-a4c0-5fe5965660e7RxCUI 2705382, 2705389, 2705393, 2705398, 2705400, 2705401, 2726116, 2726118UNII FU77B4U5Z0
- Pharmacologic class
- Interleukin-12 Antagonist; Interleukin-23 Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N451759050513followed by a unit qualifier and the quantityPackage 51759-0505-13. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
SELARSDI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn’s disease (CD). ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) 1.1 Plaque Psoriasis (PsO) SELARSDI™ is indicated for the treatment of adults and pediatric patients 6 years of age and older with …
Excerpt only. Read the full label for complete information.
Other NDCs under BLA 761343
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Ustekinumab-aekn | Ustekinumab-aekn 45 mg/.5mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-413 |
| Ustekinumab-aekn | Ustekinumab-aekn 90 mg/mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-414 |
| Selarsdiustekinumab-aekn | Ustekinumab-aekn 130 mg/26mL | Injection, SolutionIntravenous | Teva Pharmaceuticals USA, Inc. | 51759-708 |
| Ustekinumab-aekn | Ustekinumab-aekn 45 mg/.5mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-709 |
| Ustekinumab-aekn | Ustekinumab-aekn 90 mg/mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-710 |
| Selarsdiustekinumab-aekn | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | A-S Medication Solutions | 50090-7769 |
| Selarsdiustekinumab-aekn | Ustekinumab-aekn 90 mg/mL | Injection, SolutionSubcutaneous | Teva Pharmaceuticals USA, Inc. | 51759-607 |